Streetbeat News

NUMIF

Numinus Wellness Inc.

http://rojoresources.com/

CEO

Allen Morishita

Industry

Testing Laboratories

Open

0.02

Mkt cap

6.2M

Volume

14K

High

0.03

P/E Ratio

-0.32

52-wk high

0.09

Low

0.02

Div yield

N/A

52-wk low

0.02

Numinus Wellness Inc. has announced a change in its Chief Financial Officer position. Kelvin Yang will take over as Interim CFO, replacing Melony Valleau, effective February 18, 2025.

Portfolio Pulse from

February 18, 2025 | 11:45 pm

Numinus Wellness Inc. is winding down non-operating subsidiaries to simplify its corporate structure and focus on core business areas, aiming to enhance operational efficiency and financial sustainability.

Portfolio Pulse from

February 14, 2025 | 10:15 pm

Numinus Wellness Inc. has announced a leadership change with Michael Tan appointed as CEO and Payton Nyquvest transitioning to Executive Chair. The company focuses on mental healthcare and psychedelic-assisted therapies.

Portfolio Pulse from

January 23, 2025 | 10:45 pm

Numinus Wellness Inc. has provided an update on its management cease trade order related to its annual financial filings. The order was granted by the British Columbia Securities Commission due to delays in filing its financial statements and related documents for the year ended August 31, 2024.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

Portfolio Pulse from

January 01, 2025 | 2:00 pm

Numinus Wellness has sold its U.S. wellness clinics to Stella for $3.53 million, forming a data-sharing partnership to enhance mental health care management. This move allows Numinus to focus on its business units and product development, creating an asset-light model with improved clinical support and financial stability.

Portfolio Pulse from

December 17, 2024 | 12:15 pm

Numinus Wellness Inc. has provided an update on its management cease trade order related to its annual financial filings. The order was granted by the British Columbia Securities Commission due to delays in filing its audited financial statements and related documents.

Portfolio Pulse from

December 16, 2024 | 5:15 pm

Numinus Wellness Inc. has applied for a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission to gain more time to finalize its audited annual financial statements and related documents for the year ended August 31, 2024.

Portfolio Pulse from

November 16, 2024 | 12:45 am

Numinus Wellness has announced the sale of its U.S. wellness clinics to Stella for $3.53 million and a partnership to develop a technology-driven clinic management solution. This move aims to enhance clinic efficiency and support mental health care providers.

Portfolio Pulse from

November 15, 2024 | 12:15 pm

The FDA has delayed the approval of MDMA-assisted psychotherapy for PTSD, requiring an additional phase 3 trial. Lykos Therapeutics is working to address the FDA's concerns. Meanwhile, other companies like Atai Life Sciences, Numinus Wellness, Compass Pathways, MindBio Therapeutics, and Awakn Life Sciences are advancing their psychedelic treatments for various psychiatric conditions.

Portfolio Pulse from Juan Spínelli

September 13, 2024 | 12:28 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.